Ignota Labs completed the acquisition of clinical assets from Kronos.

Ignota Labs, an AI drug turnaround company, completed the acquisition of clinical assets from Kronos, a provider of workforce management and human capital management cloud solutions. Financial terms were not disclosed. “We are acquiring assets that have demonstrated therapeutic effect, but failed in their development and were shelved despite tens of millions of dollars already invested in them. This is where Ignota Labs come in: unlocking value by turning around failing drugs so that they can quickly get back into clinical trials and bring fresh hope to the patients waiting for these drugs,” Sam Windsor, Ignota Labs CEO and Co-Founder.